%0 Journal Article
%A Matsushita, Kunihiro
%A Kaptoge, Stephen
%A Hageman, Steven Hj
%A Sang, Yingying
%A Ballew, Shoshana H
%A Grams, Morgan E
%A Surapaneni, Aditya
%A Sun, Luanluan
%A Arnlov, Johan
%A Bozic, Milica
%A Brenner, Hermann
%A Brunskill, Nigel J
%A Chang, Alex R
%A Chinnadurai, Rajkumar
%A Cirillo, Massimo
%A Correa, Adolfo
%A Ebert, Natalie
%A Eckardt, Kai Uwe
%A Gansevoort, Ron T
%A Gutierrez, Orlando
%A Hadaegh, Farzad
%A He, Jiang
%A Hwang, Shih Jen
%A Jafar, Tazeen H
%A Jassal, Simerjot K
%A Kayama, Takamasa
%A Kovesdy, Csaba P
%A Landman, Gijs W
%A Levey, Andrew S
%A Lloyd-Jones, Donald M
%A Major, Rupert W
%A Miura, Katsuyuki
%A Muntner, Paul
%A Nadkarni, Girish N
%A Nowak, Christoph
%A Ohkubo, Takayoshi
%A Pena, Michelle J
%A Polkinghorne, Kevan R
%A Sairenchi, Toshimi
%A Schaeffner, Elke
%A Schneider, Markus P
%A Shalev, Varda
%A Shlipak, Michael G
%A Solbu, Marit D
%A Stempniewicz, Nikita
%A Tollitt, James
%A Valdivielso, José M
%A van der Leeuw, Joep
%A Wang, Angela Yee Moon
%A Wen, Chi Pang
%A Woodward, Mark
%A Yamagishi, Kazumasa
%A Yatsuya, Hiroshi
%A Zhang, Luxia
%A Dorresteijn, Jannick An
%A Di Angelantonio, Emanuele
%A Visseren, Frank Lj
%A Pennells, Lisa
%A Coresh, Josef
%T Including Measures of Chronic Kidney Disease to Improve Cardiovascular Risk Prediction by SCORE2 and SCORE2-OP.
%J European journal of preventive cardiology
%V 30
%N 1
%@ 2047-4873
%C London [u.a.]
%I Sage Publ.
%M DKFZ-2022-01878
%P 8-16
%D 2023
%Z 2023 Jan 11;30(1):8-16
%X The 2021 ESC guideline on cardiovascular disease (CVD) prevention categorizes moderate and severe chronic kidney disease (CKD) as high and very-high CVD risk status regardless of other factors like age and does not include estimated glomerular filtration rate (eGFR) and albuminuria in its algorithms, SCORE2 and SCORE2-OP, to predict CVD risk. We developed and validated an 'Add-on' to incorporate CKD measures into these algorithms, using a validated approach.In 3,054,840 participants from 34 datasets, we developed three Add-ons (eGFR only, eGFR + urinary albumin-to-creatinine ratio [ACR] [the primary Add-on], and eGFR + dipstick proteinuria) for SCORE2 and SCORE2-OP. We validated c-statistics and net reclassification improvement (NRI), accounting for competing risk of non-CVD death, in 5,997,719 participants from 34 different datasets.In the target population of SCORE2 and SCORE2-OP without diabetes, the CKD Add-on (eGFR only) and CKD Add-on (eGFR + ACR) improved c-statistic by 0.006 (95
%K cardiovascular disease (Other)
%K chronic kidney disease (Other)
%K meta-analysis (Other)
%K risk prediction (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:35972749
%R 10.1093/eurjpc/zwac176
%U https://inrepo02.dkfz.de/record/181232